A Randomized, Placebo-Controlled, Optimized Titration Study of ABX-1431 in Adult Patients With Peripheral Neuropathic Pain
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Lu AG06466 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- Sponsors Abide Therapeutics; Lundbeck A/S
- 10 Jul 2019 Status changed from active, no longer recruiting to completed.
- 29 May 2019 Lundbeck A/S after having received customary regulatory approvals has acquired Abide Therapeutics Inc.
- 13 May 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.